Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker.
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems / Marletta, S., Fusco, N., Munari, E., Luchini, C., Cimadamore, A., Brunelli, M., Querzoli, G., Martini, M., Vigliar, E., Colombari, R., Girolami, I., Pagni, F., Eccher, A.. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 12:7(2022), pp. 1-16. [10.3390/jpm12071073]
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Eccher, Albino
2022
Abstract
Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jpm-12-01073-v2.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
5.56 MB
Formato
Adobe PDF
|
5.56 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
